Neoadjuvant chemotherapy enhances tumor-specific T cell immunity in patients with HPV-associated oropharyngeal cancer

BackgroundTreatment of patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) with neoadjuvant chemotherapy (NAC) results in a high rate of 5-year recurrence free survival with few patients requiring adjuvant treatment. We hypothesized that NAC enhances primary tumor HPV-specific T cell responses. MethodsHPV-specific responses in tumor infiltrating lymphocytes (TILs) before and after NAC were determined using autologous co-culture assays. ResultsGreater HPV16-specific TIL responses, sometimes polyclonal, were observed after NAC compared to before in 8 of 10 patients (80%) with PCR-verified HPV16-positive tumors. A significant association was observed between net-negative change in HPV-specific TIL response and disease relapse (p = 0.04, Mann-Whitney test), whereas pathologic complete response at time of surgery did not correlate with recurrence. ConclusionsNAC induces HPV-specific tumor T cell responses in patients with newly diagnosed HPV-associated OPSCC; whereas lack of an increase following NAC may associate with risk of relapse.

Automated summary

In this study, we found that neoadjuvant chemotherapy can enhance HPV-specific T cell responses in patients with newly diagnosed HPV-associated oropharyngeal squamous cell carcinoma, leading to a high recurrence-free survival rate. Furthermore, we observed an increase in HPV16-specific lymphocyte responses after chemotherapy in some patients. However, lack of an increase in response following chemotherapy was associated with a higher risk of relapse.